Clinical trial
Capecitabine in ER+/HER2-negative Breast Cancer
NCT07631052
Study timeline
Study start (actual)2026-07-29Date precision: day
Registry last updated2026-08-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
ER-positive, HER2-negative Breast Cancerunresolved
Breast Cancer Stage Iunresolved
Breast Cancer Stage IIunresolved
Breast Cancer Stage IIIunresolved
Interventions
CapecitabineDRUG · verified · RxNorm: capecitabine
Sponsors & collaborators
University Health Network, Torontolead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07631052 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.